Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
NCT02322229
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
62
Enrollment
INDUSTRY
Sponsor class
Conditions
Vitreomacular Traction
Vitreomacular Adhesion
Interventions
DRUG:
Ocriplasmin 0.125 mg in a 0.1 mL volume
Sponsor
Alcon Research